The prophylactic use of recombinant activated factor VII (rFVIIa - Novoseven®, Novo Nordisk, Denmark) in women with congenital factor VII deficiency during childbirth remains controversial. This evidence concerns the gene F7 and hyperinsulinemic hypoglycemia, familial, 4.